[Skip to Content]
[Skip to Content Landing]
April 11, 2001

Time Trends in the Coprescribing of Cisapride and Contraindicated Drugs in Umbria, Italy

Author Affiliations

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;285(14):1840-1841. doi:10.1001/jama.285.14.1840

To the Editor: Concern has been raised about the cardiovascular safety of cisapride following postmarketing reports of QT-interval prolongation and serious ventricular arrhythmias.1 As a consequence, the labeling of cisapride has been revised and there have been efforts to inform health care professionals about this.2,3 Despite these risk management efforts, Janssen Pharmaceutica Inc decided to stop marketing cisapride in the United States in July 2000.4 In Europe, the United Kingdom and Germany suspended licensing for the drug while its risks and benefits are being reevaluated by the European Agency for the Evaluation of Medicinal Products. The degree of prescribers' adherence to the warnings and contraindications raised by health authorities remains critical in the evaluation of the overall safety of the drug.5

First Page Preview View Large
First page PDF preview
First page PDF preview